Antibody-targeted nanoparticles have great promise as anti-cancer drugs; however, substantial developmental challenges of antibody modules prevent many candidates from reaching the clinic. Here, we describe a robust strategy for developing an EphA2-targeting antibody fragment for immunoliposomal drug delivery. A highly bioactive single-chain variable fragment (scFv) was engineered to overcome developmental liabilities, including low thermostability and weak binding to affinity purification resins. Improved thermostability was achieved by modifying the framework of the scFv, and complementarity-determining region (CDR)-H2 was modified to increase binding to protein A resins. The results of our engineering campaigns demonstrate that it is possible, using focused design strategies, to rapidly improve the stability and manufacturing characteristics of an antibody fragment for use as a component of a novel therapeutic construct.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240644PMC
http://dx.doi.org/10.1080/19420862.2016.1259047DOI Listing

Publication Analysis

Top Keywords

single-chain variable
8
variable fragment
8
antibody fragment
8
improving developability
4
developability anti-epha2
4
anti-epha2 single-chain
4
fragment
4
fragment nanoparticle
4
nanoparticle targeting
4
targeting antibody-targeted
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!